Back
Global X Nasdaq 100® Covered Call&Gr ETF Vs. Alnylam Pharmaceuticals Industry Stock Comparison
Buy
60
QYLG
Global X Nasdaq 100® Covered Call&Gr ETF
Last Price:
32.03
Seasonality Move:
6.05%
Sell
35
ALNY
Alnylam Pharmaceuticals
Last Price:
275.08
Seasonality Move:
4.48%
Buy
60
Global X Nasdaq 100® Covered Call&Gr ETF (QYLG)
is a Buy
Is Global X Nasdaq 100® Covered Call&Gr ETF a Buy, Sell or Hold?
- The current Global X Nasdaq 100® Covered Call&Gr ETF [QYLG] share price is $32.09. The Score for QYLG is 60, which is 20% above its historic median score of 50, and infers lower risk than normal.
- QYLG is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Sell
35
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy, Sell or Hold?
- The current Alnylam Pharmaceuticals [ALNY] share price is $274.91. The Score for ALNY is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.
- ALNY is currently trading in the 30-40% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
QYLG Stock Price Chart
What is Global X Nasdaq 100® Covered Call&Gr ETF's stock price today?
-
The Global X Nasdaq 100® Covered Call&Gr ETF share price today is $32.09
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and QYLG is experiencing slight selling pressure.
ALNY Stock Price Chart
What is Alnylam Pharmaceuticals's stock price today?
-
The Alnylam Pharmaceuticals share price today is $274.91
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and ALNY is experiencing slight buying pressure.
QYLG Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.27 | Buy |
| Relative Strength Index (14 RSI): | 61.71 | Buy |
| Chaikin Money Flow: | -1302 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (30.89 - 31.97) | Buy |
| Bollinger Bands (100): | (30.4 - 31.94) | Buy |
ALNY Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 3.58 | Buy |
| Relative Strength Index (14 RSI): | 58.54 | Buy |
| Chaikin Money Flow: | 227264 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (257.28 - 277.8) | Buy |
| Bollinger Bands (100): | (173.47 - 275.75) | Buy |
QYLG Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 31.95 | Buy |
| 20-day SMA: | 31.42 | Buy |
| 50-day SMA: | 31.08 | Buy |
| 200-day SMA: | 30.46 | Buy |
| 8-day EMA: | 31.92 | Buy |
| 20-day EMA: | 31.61 | Buy |
| 50-day EMA: | 31.33 | Buy |
| 200-day EMA: | 30.29 | Buy |
ALNY Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 273.53 | Buy |
| 20-day SMA: | 264.94 | Buy |
| 50-day SMA: | 262.48 | Buy |
| 200-day SMA: | 194.67 | Buy |
| 8-day EMA: | 272.54 | Buy |
| 20-day EMA: | 269.21 | Buy |
| 50-day EMA: | 257.72 | Buy |
| 200-day EMA: | 211.82 | Buy |
Global X Nasdaq 100® Covered Call&Gr ETF Earnings Growth & QYLG Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Alnylam Pharmaceuticals Earnings Growth & ALNY Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.57 per share, an increase next quarter of $0.47 per share, an increase this year of $1.33 per share, and an increase next year of $0.70 per share.
Global X Nasdaq 100® Covered Call&Gr ETF Technical Analysis
| Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | Sep 23 | Sep 24 | Sep 25 | Sep 26 | Sep 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 16 | 17 | 18 | 19 | 20 | 23 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Alnylam Pharmaceuticals Technical Analysis
| Sep 16 | Sep 17 | Sep 18 | Sep 19 | Sep 20 | Sep 23 | Sep 24 | Sep 25 | Sep 26 | Sep 27 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep | ||||||||||
| 16 | 17 | 18 | 19 | 20 | 23 | 24 | 25 | 26 | 27 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||